

IN THE CLAIMS:

Please cancel claims 31-34.

Please amend claims 1, 3, 5-6, 15-16, 18, 22, 24, 29, 30, 36, and 39-61 as follows:

A2

1. (Amended) A method of ameliorating sexual dysfunction in a mammal comprising nasally administering a therapeutically effective amount of a dopamine receptor agonist in an aqueous formulation for intranasal delivery to said mammal before, during or after sexual activity which is intranasally effective to alleviate said sexual dysfunction without causing substantial intolerable adverse side effects to said mammal.

Sub 3

3. (Amended) A pharmaceutical composition for treating sexual dysfunction in a mammal comprising a therapeutically effective amount of a dopamine receptor agonist in an aqueous formulation for intranasal delivery, wherein said pharmaceutical composition is intranasal effective to alleviate said sexual dysfunction without causing substantial intolerable adverse side effects in said mammal.

A4

5. (Amended) The pharmaceutical composition of Claim 4, wherein said apomorphine is dispersed in an aqueous spray formulation.

6. (Amended) The pharmaceutical composition of Claim 4, wherein said aqueous formulation for intranasal delivery comprises a buffer to maintain the pH of said dopamine receptor agonist, a pharmaceutically acceptable thickening agent and a humectant.

A5

15. (Amended) A pharmaceutical composition for treating male or female sexual dysfunction in a mammalian subject comprising a therapeutically effective amount of a dopamine receptor agonist dispersed in an aqueous formulation for intranasal delivery comprising a buffer to maintain a pH of the formulation, a pharmaceutically acceptable thickening agent and a humectant, wherein said pharmaceutical composition is intranasally effective to alleviate said sexual dysfunction and does not cause substantial intolerable adverse side effects when administered to said mammal.

AS

16. (Amended) The pharmaceutical composition of Claim 15, wherein said dopamine receptor agonist is selected from the group including apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

17. (Amended) The pharmaceutical composition of Claim 16, wherein said chemically modified equivalents comprise a pro-drug.

PL

22. (Amended) A method of administering a therapeutically effective amount of a dopamine receptor agonist to a mammal through a nasal membrane thereof for treatment of male or female sexual dysfunction in said mammal comprising delivering to said nasal membrane a therapeutically effective amount of said dopamine receptor agonist which does not cause substantial intolerable adverse side effects in said mammal, wherein said dopamine receptor agonist is dispersed in an aqueous formulation for intranasal delivery comprising a pharmaceutically acceptable a buffer, a thickening agent and a humectant.

PM

24. (Amended) An intranasal dosage unit for treating impotency or erectile dysfunction in a mammal comprising an effective amount of a dopamine receptor agonist in an aqueous formulation for intranasal delivery comprising a buffer, wherein said dosage unit does not cause substantial intolerable adverse side effects in said mammal and an erection is produced in said mammal within about 60 minutes of administering said dosage unit to a nasal mucosa of said mammal.

AS

29. (Amended) The intranasal dosage unit of Claim 24, wherein said aqueous formulation is administered to said mammal as an aqueous spray.

30. (Amended) The intranasal dosage unit of Claim 29, wherein said aqueous formulation is selected from the group consisting of aqueous gels, aqueous suspensions, aqueous liposomal dispersions, aqueous emulsions, aqueous microemulsions and combinations thereof.

AG

36. (Amended) The intranasal dosage unit of Claim 24, wherein said buffer is selected to have a pH of from about 3 to about 3.5.

39. (Amended) A pharmaceutical composition according to claim 3, wherein said dopamine receptor agonist has been dispersed with a solubilizing agent to improve its solubility.

40. (Amended) The pharmaceutical composition of Claim 39, wherein said dopamine receptor agonist is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

41. (Amended) The pharmaceutical composition of Claim 39, wherein said system comprises glycerin.

42. (Amended) The pharmaceutical composition of Claim 39, wherein said solubilizing agent comprises a glycol derivative.

43. (Amended) The pharmaceutical composition of Claim 42, wherein said glycol derivative is propylene glycol.

44. (Amended) The pharmaceutical composition of Claim 42, wherein said glycol derivative is polyethylene glycol.

45. (Amended) The pharmaceutical composition of Claim 39, wherein said solubilizing agent comprises a sugar alcohol.

46. (Amended) The pharmaceutical composition of Claim 39, wherein said solubilizing agent comprises propylene glycol and glycerin.

47. (Amended) The pharmaceutical composition of Claim 39, wherein said solubilizing agent comprises ascorbic acid and water.

48. (Amended) The pharmaceutical composition of Claim 39, wherein said solubilizing agent comprises sodium ascorbate and water.

49. (Amended) The pharmaceutical composition of Claim 39, wherein said solubilizing agent comprises sodium metabisulfite and water.

PL 0
10
0622900
Docket No.
50
51
52
53
54
55
56
57
58
59

50. (Amended) A pharmaceutical composition for treating male erectile dysfunction in a mammal comprising a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in an aqueous formulation for intranasal delivery comprising a stabilizing agent to improve stability of said dopamine receptor agonist in the formulation.

51. (Amended) The pharmaceutical composition of Claim 50, wherein said dopamine receptor agonist is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

52. (Amended) The pharmaceutical composition of Claim 50, wherein said stabilizing agent comprises glycerin.

53. (Amended) The pharmaceutical composition of Claim 50, wherein said stabilizing agent comprises a glycol derivative.

54. (Amended) pharmaceutical composition of Claim 53, wherein said glycol derivative is propylene glycol.

55. (Amended) The pharmaceutical composition of Claim 53, wherein said glycol derivative is polyethylene glycol.

56. (Amended) The pharmaceutical composition of Claim 50, wherein said stabilizing agent comprises a sugar alcohol.

57. (Amended) The pharmaceutical composition of Claim 50, wherein said stabilizing agent comprises propylene glycol and glycerin.

58. (Amended) The pharmaceutical composition of Claim 50, wherein said stabilizing agent comprises polyethylene glycol 400.

59. (Amended) The pharmaceutical composition of Claim 50, wherein said stabilizing agent comprises ascorbic acid and water.

60. (Amended) The pharmaceutical composition of Claim 50, wherein
said stabilizing agent comprises sodium ascorbate and water.

61. (Amended) The pharmaceutical composition of Claim 50, wherein
said stabilizing agent comprises sodium metabisulfite and water.

DOCKET NO.: NPCI-0294/719-127CON3